Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model

Vid Leko1, Gemma J Park, Uyen Lao

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.

Plos One
|June 27, 2013
PubMed

Insights

Sirtuin 1 (SIRT1) deficiency in intestinal cells reduces intestinal tumor growth and size in mice. This suggests SIRT1 promotes tumor development by helping cancer cells survive.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Sirtuin 1 (SIRT1) is a NAD(+)-dependent deacetylase involved in aging, metabolism, and cancer.
  • Previous studies on SIRT1's role in intestinal tumorigenesis have yielded conflicting results.
  • Resolving these discrepancies is crucial for understanding SIRT1's function in cancer.

Purpose of the Study:

  • To investigate the specific role of intestinal SIRT1 in intestinal tumor formation.
  • To clarify the contradictory findings regarding SIRT1's function in tumorigenesis.
  • To determine whether SIRT1 acts as a tumor suppressor or promoter in the intestines.

Main Methods:

  • Utilized a mouse model (APC(+/min)) for intestinal tumorigenesis.
  • Generated mice with enterocyte-specific inactivation of SIRT1.
  • Crossed these mice with APC(+/min) mice to study polyp development in progeny.

Main Results:

  • SIRT1 deficiency significantly reduced total polyp surface area, average polyp size, and the number of larger polyps.
  • Tumors in SIRT1-deficient mice showed a marked increase in apoptosis (programmed cell death).
  • These findings indicate SIRT1 influences both the quantity and size of intestinal tumors.

Conclusions:

  • SIRT1 acts as a tumor promoter in the APC(+/min) mouse model of intestinal tumorigenesis.
  • Intestinal SIRT1 deficiency leads to reduced tumor burden and increased cancer cell death.
  • SIRT1 may promote tumor growth by enhancing the survival of intestinal cancer cells.